<SEC-DOCUMENT>0001193125-25-125879.txt : 20250523
<SEC-HEADER>0001193125-25-125879.hdr.sgml : 20250523
<ACCEPTANCE-DATETIME>20250523163218
ACCESSION NUMBER:		0001193125-25-125879
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250523
DATE AS OF CHANGE:		20250523

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Climb Bio, Inc.
		CENTRAL INDEX KEY:			0001768446
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				832273741
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40708
		FILM NUMBER:		25982935

	BUSINESS ADDRESS:	
		STREET 1:		20 WILLIAM STREET
		STREET 2:		SUITE 145
		CITY:			WELLESLEY HILLS
		STATE:			MA
		ZIP:			02481
		BUSINESS PHONE:		1-866-857-2596

	MAIL ADDRESS:	
		STREET 1:		20 WILLIAM STREET
		STREET 2:		SUITE 145
		CITY:			WELLESLEY HILLS
		STATE:			MA
		ZIP:			02481

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eliem Therapeutics, Inc.
		DATE OF NAME CHANGE:	20190219
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d847363ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy
Statement Pursuant to Section&nbsp;14(a) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No.&#8195;) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&#8194;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other
than the Registrant&#8194;&#9744; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material under &#167; <FONT STYLE="white-space:nowrap">240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Climb Bio, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name
of Registrant as Specified In Its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check all boxes that apply): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g847363g0523052744275.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUPPLEMENT TO PROXY STATEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2025 ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>To Be Held on Wednesday, June&nbsp;4, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Climb Bio, Inc. (the &#147;Company&#148;) is filing this supplement on May&nbsp;23, 2025 to update the Company&#146;s definitive proxy statement filed with
the U.S. Securities and Exchange Commission (the &#147;SEC&#148;) on April&nbsp;25, 2025 (the &#147;Proxy Statement&#148;), and made available to the Company&#146;s stockholders in connection with the solicitation of proxies on behalf of the
Company&#146;s board of directors (the &#147;Board&#148;) for its annual meeting of stockholders to be held on June&nbsp;4, 2025, or any adjournment or postponement thereof (the &#147;Annual Meeting&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company urges you to read the Proxy Statement and this supplement in their entirety. Except as specifically supplemented by the information contained
herein, all information set forth in the Proxy Statement remains unchanged. To the extent that information in this supplement differs from or updates information contained in the Proxy Statement, the information in this supplement is more current.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Departure of Chief Operating Officer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
May&nbsp;23, 2025, the Company and Brett Kaplan, M.D., its Chief Operating Officer and principal financial officer, mutually agreed that Dr.&nbsp;Kaplan would separate from the Company, effective May&nbsp;23, 2025 (the &#147;Separation Date&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, on the Separation Date, the Company entered into a Separation and Release of Claims Agreement (the &#147;Separation Agreement&#148;) with
Dr.&nbsp;Kaplan, governing the terms of his separation from the Company. Pursuant to the Separation Agreement and subject to Dr.&nbsp;Kaplan&#146;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of an additional release of
claims in favor of the Company and its affiliates, Dr.&nbsp;Kaplan is entitled to: (1)&nbsp;a lump sum cash payment equal to three months of his base salary and (2)&nbsp;payments for the continuation of his health coverage under COBRA for a period
of up to three months from the Separation Date. The Separation Agreement also provides for, among other things, <FONT STYLE="white-space:nowrap">non-disclosure,</FONT> <FONT STYLE="white-space:nowrap">non-disparagement</FONT> and cooperation
obligations applicable to Dr.&nbsp;Kaplan and a reaffirmation of Dr.&nbsp;Kaplan&#146;s obligations under the employee confidential information, inventions assignment, <FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> agreement he previously entered into with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the Separation Agreement has been
filed as Exhibit 10.1 to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed by the Company with the SEC on May&nbsp;23, 2025. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Appointment of Interim Principal Financial Officer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Separation Date, the Board appointed Aoife Brennan as the Company&#146;s interim principal financial officer, effective as of May&nbsp;24, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no changes to Dr.&nbsp;Brennan&#146;s compensatory plans or arrangements in connection with her appointment as interim principal financial officer.
</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g847363g0523052744275.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g847363g0523052744275.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T /$# 2(  A$! Q$!_\0
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9%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
